{"id":"a006","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, A006 reduces glucose reabsorption in the kidneys, leading to decreased glucose levels in the blood. This mechanism is particularly effective in patients with type 2 diabetes, as it helps to lower blood sugar levels and improve glycemic control.","oneSentence":"A006 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:03.383Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT01189396","phase":"PHASE2","title":"Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2010-07","conditions":"Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":27},{"nctId":"NCT01581177","phase":"PHASE2","title":"Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2012-04","conditions":"Asthma","enrollment":23},{"nctId":"NCT01174732","phase":"PHASE2","title":"Dose-Ranging Study of A006 DPI, in Adult Asthma Patients","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2010-07","conditions":"Asthma, Bronchospasm","enrollment":26},{"nctId":"NCT02210806","phase":"PHASE2","title":"Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2014-07","conditions":"Asthma","enrollment":22},{"nctId":"NCT02271334","phase":"PHASE2","title":"Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2014-08","conditions":"Asthma","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"A006","genericName":"A006","companyName":"Amphastar Pharmaceuticals, Inc.","companyId":"amphastar-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A006 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}